Acrivon Therapeutics Inc (ACRV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2020 | 12-2017 | |
| Cash Flows From Operating Activities | ||
| Net Income | -5,306 | N/A |
| Depreciation Amortization | 13 | N/A |
| Accounts payable and accrued liabilities | 81 | N/A |
| Other Working Capital | 317 | N/A |
| Other Operating Activity | 2,092 | 0 |
| Operating Cash Flow | $-2,803 | $N/A |
| Cash Flows From Investing Activities | ||
| PPE Investments | -15 | N/A |
| Investing Cash Flow | $-15 | $N/A |
| Cash Flows From Financing Activities | ||
| Change In Short Term Borrowing | 58 | N/A |
| Other Financing Activity | 2,831 | 0 |
| Financing Cash Flow | $2,889 | $N/A |
| Beginning Cash Position | 1,919 | N/A |
| End Cash Position | 1,990 | N/A |
| Net Cash Flow | $71 | $N/A |
| Free Cash Flow | ||
| Operating Cash Flow | -2,803 | N/A |
| Capital Expenditure | -15 | N/A |
| Free Cash Flow | -2,818 | 0 |